← XTL BIOPHARMACEUTICALS LTD
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Loss for the Year | — | ($781k) | $3.0m | ($1.3m) | ($782k) | $435k | ($1.3m) | ($1.8m) | ($1.0m) | ($7.0m) | — | |
| Net Income | — | — | — | — | — | — | ($1.3m) |
($1.8m)
-32.20%
|
($1.0m)
+42.37%
|
($7.0m)
-578.58%
|
($7.0m)
0.00%
|
|
| Profit or Loss | ($2.5m) | ($781k) | $3.0m | ($1.3m) | ($3.0m) | $435k | ($1.3m) | ($1.8m) | ($1.0m) | — | — | |
| Depreciation and amortization | — | — | — | — | $1k | $1k | $1k | $0 | $199k | $0 | $0 | |
| Depreciation Amortization Depletion | — | — | — | — | — | — | $1k | $0 | $199k | $0 | $0 | |
| Deferred Income Tax | — | — | — | — | — | — | $0 | $0 | ($130k) | $0 | $0 | |
| Deferred Tax | — | — | — | — | — | — | $0 | $0 | ($130k) | $0 | $0 | |
| Adjustments For Share-Based Payments | $127k | $39k | $22k | $5k | $51k | $37k | $14k | $3k | $264k | — | — | |
| Share-based payment expense | — | — | — | — | $51k | $37k | $14k | $3k | $264k | $346k | — | |
| Asset Impairment Charge | — | — | — | — | — | — | — | $0 | $0 | $531k | $531k | |
| Change In Working Capital | — | — | — | — | — | — | ($19k) | $64k | $189k | ($2k) | ($2k) | |
| Decrease in trade receivables | — | — | — | — | — | — | — | — | $39k | $157k | — | |
| Change In Receivables | — | — | — | — | — | — | $0 | $0 | $39k | $157k | $157k | |
| Changes In Account Receivables | — | — | — | — | — | — | $0 | $0 | $39k | $157k | $157k | |
| Increase (decrease) in accounts payable | — | ($157k) | ($47k) | ($21k) | $22k | ($23k) | ($44k) | $19k | $208k | ($187k) | ($187k) | |
| Decrease (increase) in prepaid expenses and other current assets | — | — | — | — | — | ($31k) | $25k | $45k | ($58k) | $28k | — | |
| Cash flows from investing activities: | ||||||||||||
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | — | $1k | — | — | — | — | — | — | — | — | — | |
| Capital Expenditure | — | — | — | — | — | — | — | — | ($54k) | — | ($54k) | |
| Revaluation of marketable securities | — | — | ($2.8m) | $574k | ($138k) | ($747k) | $1.5m | $1.0m | ($167k) | ($5k) | — | |
| Net Other Investing Changes | — | — | — | — | — | — | — | — | ($400k) | ($250k) | ($250k) | |
| Cash flows from financing activities: | ||||||||||||
| Repayments Of Borrowings Classified As Financing Activities | — | — | — | — | — | — | — | — | $13k | — | — | |
| Issuance Of Debt | — | — | — | — | — | — | — | $0 | $0 | $208k | $208k | |
| Long Term Debt Issuance | — | — | — | — | — | — | — | $0 | $0 | $208k | $208k | |
| Net Issuance Payments Of Debt | — | — | — | — | — | — | $0 | $0 | ($13k) | $208k | $208k | |
| Net Short Term Debt Issuance | — | — | — | — | — | — | $0 | $0 | ($13k) | $0 | $0 | |
| Repayment Of Debt | — | — | — | — | — | — | $0 | $0 | ($13k) | $0 | $0 | |
| Short Term Debt Payments | — | — | — | — | — | — | $0 | $0 | ($13k) | $0 | $0 | |
| Common Stock Issuance | — | — | — | — | — | — | $0 | $0 | $1.5m | $0 | $0 | |
| Issuance Of Capital Stock | — | — | — | — | — | — | $0 | $0 | $1.5m | $0 | $0 | |
| Cash and cash equivalents at the beginning of the year | — | $3.3m | $3.3m | $4.5m | $3.6m | $3.0m | $2.1m | $1.4m | $371k | $76k | — | |
| Beginning Cash Position | — | — | — | — | — | — | $3.0m | $2.1m | $1.4m | $371k | $371k | |
| Losses from exchange rate differences on cash and cash equivalents | — | $2k | ($4k) | $3k | $6k | $6k | $10k | $27k | ($15k) | — | — | |
| Exchange rate differences | — | — | — | — | — | — | — | $27k | $14k | ($35k) | — | |
| Effect Of Exchange Rate Changes | — | — | — | — | — | — | ($10k) | ($27k) | ($15k) | $0 | $0 | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Additional Financial Items | ||||||||||||
| Adjustments For Decrease Increase In Trade Account Receivable | — | — | — | — | — | — | — | — | $39k | — | — | |
| Adjustments For Finance Costs | — | — | — | — | — | — | — | $27k | $14k | — | — | |
| Adjustments For Increase Decrease In Trade Account Payable | ($101k) | ($13k) | ($47k) | ($21k) | $22k | ($23k) | ($44k) | $19k | $208k | — | — | |
| General and Administrative Expense | $1.3m | $1.2m | $755k | $807k | $910k | $1.0m | $850k | $734k | $1.6m | — | — | |
| Goodwill | — | — | — | — | — | — | — | — | $3.2m | — | $531k | |
| Interest Received Classified As Operating Activities | — | ($4k) | ($87k) | ($93k) | ($33k) | — | — | — | — | — | — | |
| Purchase Of Intangible Assets Classified As Investing Activities | $64k | — | — | — | — | — | — | — | — | — | — | |
| Purchase of fixed assets | — | — | — | ($2k) | ($1k) | — | — | — | ($54k) | — | — | |
| Interest from bank deposit | — | $4k | $74k | $93k | $33k | $8k | $36k | $41k | $34k | — | — | |
| Issuance of shares and warrants | — | — | — | — | — | $385k | — | — | $1.5m | — | — | |
| Decrease in cash and cash equivalents | — | — | — | $1.2m | ($818k) | ($656k) | ($865k) | ($666k) | ($1.0m) | ($295k) | — | |
| Revaluation of warrants | — | ($765k) | ($974k) | ($584k) | $2.2m | ($719k) | ($1.1m) | — | ($926k) | ($1.1m) | — | |
| Interest income | — | — | ($87k) | ($93k) | ($33k) | ($8k) | ($36k) | ($41k) | ($34k) | ($60k) | — | |
| Net operating asset and liability | — | — | — | — | — | — | — | $64k | $189k | ($2k) | — | |
| Cash Flow From Continuing Financing Activities | — | — | — | — | — | — | $0 | $0 | $1.4m | $208k | $208k | |
| Cash Flow From Continuing Investing Activities | — | — | — | — | — | — | $36k | $41k | ($844k) | $522k | $522k | |
| Change In Account Payable | — | — | — | — | — | — | ($44k) | $19k | $208k | ($187k) | ($187k) | |
| Change In Cash Supplemental As Reported | — | — | — | — | — | — | ($865k) | ($666k) | ($1.0m) | ($295k) | — | |
| Change In Payable | — | — | — | — | — | — | ($44k) | $19k | $208k | ($187k) | ($187k) | |
| Change In Prepaid Assets | — | — | — | — | — | — | $25k | $45k | ($58k) | $28k | $28k | |
| Changes In Cash | — | — | — | — | — | — | ($865k) | ($666k) | ($1.0m) | ($295k) | ($295k) | |
| End Cash Position | — | — | — | — | — | — | $2.1m | $1.4m | $371k | $76k | $76k | |
| Financing Cash Flow | — | — | — | — | — | — | $0 | $0 | $1.4m |
$208k
-85.63%
|
$208k
0.00%
|
|
| Free Cash Flow | — | — | — | — | — | — | ($901k) | ($707k) | ($1.7m) | ($1.0m) | ($1.0m) | |
| Gain Loss On Investment Securities | — | — | — | — | — | ($719k) | ($1.1m) | — | ($926k) | ($1.1m) | ($1.1m) | |
| Gain Loss On Sale Of Business | — | — | — | — | — | — | — | $0 | $0 | $6.2m | $6.2m | |
| Interest Received CFI | — | — | — | — | — | — | $36k | $41k | $34k | $0 | $0 | |
| Investing Cash Flow | — | — | — | — | — | — | $36k | $41k | ($844k) | $522k | $522k | |
| Net Business Purchase And Sale | — | — | — | — | — | — | $0 | $0 | ($410k) | ($5k) | ($5k) | |
| Net Foreign Currency Exchange Gain Loss | — | — | — | — | — | $6k | $10k | $27k | — | — | $27k | |
| Net Investment Purchase And Sale | — | — | — | — | — | — | $0 | $0 | ($14k) | $777k | $777k | |
| Net PPE Purchase And Sale | — | — | — | — | — | — | $0 | $0 | ($54k) | $0 | $0 | |
| Operating Gains Losses | — | — | — | — | — | — | ($1.1m) | $27k | ($926k) | $5.1m | $5.1m | |
| Other Non Cash Items | — | — | — | — | — | — | ($26k) | ($14k) | ($20k) | ($34k) | — | |
| Proceeds From Stock Option Exercised | — | — | — | — | — | $385k | $0 | $0 | — | — | $0 | |
| Purchase Of Business | — | — | — | — | — | — | $0 | $0 | ($410k) | ($5k) | ($5k) | |
| Purchase Of Investment | — | — | — | — | — | — | $0 | $0 | ($14k) | $0 | $0 | |
| Purchase Of PPE | — | $2k | $2k | $2k | $1k | $1k | $0 | $0 | ($54k) | $0 | ($54k) | |
| Sale Of Investment | — | — | — | — | — | $0 | — | $0 | $0 | $777k | $777k | |
| Stock Based Compensation | — | — | — | — | — | — | $14k | $3k | $264k | $346k | $346k | |
| Unrealized Gain Loss On Investment Securities | — | — | — | — | — | — | $1.5m | $1.0m | ($167k) | ($5k) | ($5k) |